Streetbeat News

Analyst Ratings

PRQR

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on ProQR Therapeutics (NASDAQ:PRQR) and maintained a $5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:15 am

FHTX

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:14 am

BDN

HCM

IEP

NET

PKX

SCLX

SOHU

Several stocks recorded losses in Monday's pre-market trading session, including HUTCHMED, Scilex Holding Company, POSCO Holdings, Sohu.com, Cloudflare, Brandywine Realty Trust, and Icahn Enterprises. Notably, Sohu.com reported weak quarterly earnings, and Cloudflare was downgraded from Neutral to Sell by Guggenheim with a $50 price target. Icahn Enterprises also saw a drop after reporting weak Q2 results and cutting its quarterly distribution by 50%.

Portfolio Pulse from Lisa Levin

August 07, 2023 | 10:14 am

SAGE

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:13 am

ACIU

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on AC Immune (NASDAQ:ACIU) and maintained a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:13 am

VIR

HC Wainwright & Co. analyst Patrick Trucchio maintains a 'Buy' rating on Vir Biotechnology (NASDAQ:VIR) but lowers the price target from $100 to $95.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:08 am

ALNY

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $405.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:07 am

CCO

Clear Channel Outdoor (NYSE:CCO) reported Q2 losses of $(0.08) per share, missing the analyst consensus estimate of $(0.06) by 28.33 percent. This is a 14.44 percent increase over losses from the same period last year. The company also reported quarterly sales of $637.24 million, missing the analyst consensus estimate of $639.87 million by 0.41 percent, a 0.95 percent decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2023 | 10:06 am

SAND

HC Wainwright & Co. analyst Heiko Ihle maintains a 'Buy' rating on Sandstorm Gold (NYSE:SAND) and raises the price target from $12.5 to $13.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:05 am

CLMT

HC Wainwright & Co. analyst Amit Dayal has reiterated a 'Buy' rating on Calumet Specialty Prods (NASDAQ:CLMT) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 07, 2023 | 10:04 am